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Introduction
RASopathies (Noonan syndrome (NS) and Noonan-related
syndromes) are neurodevelopmental syndromes resulting
from germline mutations in genes that participate in the
rat sarcoma/mitogen-activated protein kinases (RAS/
MAPK) pathway (PTPN11, SOS1, RAF, KRAS or NRAS
and SHOC2). Some monogenic conditions are associated
with the development of systemic lupus erythematosus
(SLE), and a few reports described the association of SLE,
with NS.
Objectives
We aim to search for a relationship between RASopathy
and the development of SLE.
Methods
We reported for the first time on a 13-year-old boy with
NS with loose anagen hair (NSLAH) resulting from muta-
tion in SHOC2 who developed an autoimmune disorder
which fulfilled four American College or Rheumatology
(ACR) criteria for the classification of SLE (polyarthritis,
pericarditis, antinuclear antibodies, anti-DNA antibodies).
The case report then prompted a literature review by a
systematic search for English and French articles on the
subjects of RASopathies and SLE that had English
abstracts in PubMed from 1966 to 2012.
Results
We identified seven additional patients with RASopathy
and SLE. The male-to-female ratio was 1:1, and age at
onset of SLE ranged from 5 to 32 years. The most com-
mon features were polyarthritis (7/8 patients), auto-
immune cytopenia (4/8 patients) and pericarditis (4/8
patients) while only one patient presented with skin
involvement.
Conclusion
The association of two rare diseases in eight patients
suggests that RASopathies may be associated with the
development of SLE, which is characterized by a higher
male-to-female ratio, a lower rate of skin involvement
and a higher rate of pericarditis than “classic” SLE.
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